Negotiate all drug prices.

Marie Gluesenkamp Perez · Washington · Democratic

policy impact 0.68 specificity 0.80 extraction confidence 97%

Contest this claim

Occurrences

Evidence

CMS lists selected-drug cohorts for 2026, 2027, and 2028, including 10 first-cycle drugs, 15 second-cycle drugs, and 15 third-cycle drugs. CMS says third-cycle negotiations occur in 2026 and any prices take effect in 2028.

The active federal program negotiates prices for selected Medicare drugs, not all prescription drug prices. This is a partial implementation of the promise, with no sign in the lookback window that all drug prices are now negotiated.

partial later_term

Selected Drugs and Negotiated Prices | CMS
secondary · model gpt-5.5 · confidence 93%

Contest this evidence item

The Supreme Court order list under certiorari denied includes AstraZeneca, Janssen, Bristol Myers Squibb, Novo Nordisk, and Boehringer Ingelheim challenges involving HHS or the Department of HHS.

A major legal challenge to Medicare drug-price negotiation was not taken up by the Supreme Court during the lookback window, leaving the limited negotiation program in place. This supports partial delivery, not all-drug negotiation.

partial later_term

051826zor_h315.pdf
secondary · model gpt-5.5 · confidence 88%

Contest this evidence item

Congress.gov says H.R.6166 would expand the drug price negotiation program, apply prescription drug inflation rebates to the commercial market, and establish out-of-pocket limits for private insurance; its tracker status remains Introduced after House committee referral.

A bill matching the broader goal of expanding negotiation and commercial-market drug-price protections has not become law as of this refresh. That leaves the broader 'all drug prices' commitment unresolved.

unresolved later_term

All Information (Except Text) for H.R.6166 - Lowering Drug Costs for American Families Act
secondary · model gpt-5.5 · confidence 90%

Contest this evidence item

Perez's office says she joined a bipartisan bill to bring down health care costs, including ending hidden spread pricing, severing PBM profits from drug prices, and requiring full rebate pass-through.

Perez took concrete action related to prescription-drug affordability and PBM pricing, but the described bill does not negotiate all drug prices. It supports effort toward a narrower, partial drug-cost objective.

partial later_term A for effort

Gluesenkamp Perez Co-Leads Bipartisan Bill to Prevent ACA Premium Spikes and Protect Affordable Healthcare
secondary · model gpt-5.5 · confidence 82%

Contest this evidence item

Assessments

partial later_term A for effort

The promise was to negotiate all drug prices, which has not been fully delivered. The federal Medicare negotiation program covers selected cohorts of Medicare drugs for 2026, 2027, and 2028, not all prescription drug prices, so the achieved policy is materially narrower than the claim. Perez has taken legislative action on drug affordability and related pricing reforms, but the broader all-drug negotiation outcome has not become law. Because there is a real but incomplete policy implementation and candidate effort toward the area, partial credit is appropriate rather than delivered or never.

provider codex_cli · model gpt-5.5 · confidence 90%